238 related articles for article (PubMed ID: 27237586)
1. Mutational signature of aristolochic acid: Clue to the recognition of a global disease.
Rosenquist TA; Grollman AP
DNA Repair (Amst); 2016 Aug; 44():205-211. PubMed ID: 27237586
[TBL] [Abstract][Full Text] [Related]
2. Aristolactam-DNA adducts are a biomarker of environmental exposure to aristolochic acid.
Jelaković B; Karanović S; Vuković-Lela I; Miller F; Edwards KL; Nikolić J; Tomić K; Slade N; Brdar B; Turesky RJ; Stipančić Ž; Dittrich D; Grollman AP; Dickman KG
Kidney Int; 2012 Mar; 81(6):559-67. PubMed ID: 22071594
[TBL] [Abstract][Full Text] [Related]
3. Aristolochic acid nephropathy: Harbinger of a global iatrogenic disease.
Grollman AP
Environ Mol Mutagen; 2013 Jan; 54(1):1-7. PubMed ID: 23238808
[TBL] [Abstract][Full Text] [Related]
4. Aristolochic acid-induced upper tract urothelial carcinoma in Taiwan: clinical characteristics and outcomes.
Chen CH; Dickman KG; Huang CY; Moriya M; Shun CT; Tai HC; Huang KH; Wang SM; Lee YJ; Grollman AP; Pu YS
Int J Cancer; 2013 Jul; 133(1):14-20. PubMed ID: 23292929
[TBL] [Abstract][Full Text] [Related]
5. Aristolochic acid and its effect on different cancers in uro-oncology.
Rebhan K; Ertl IE; Shariat SF; Grollman AP; Rosenquist T
Curr Opin Urol; 2020 Sep; 30(5):689-695. PubMed ID: 32701724
[TBL] [Abstract][Full Text] [Related]
6. Chemical and molecular basis of the carcinogenicity of Aristolochia plants.
Schmeiser HH; Stiborovà M; Arlt VM
Curr Opin Drug Discov Devel; 2009 Jan; 12(1):141-8. PubMed ID: 19152223
[TBL] [Abstract][Full Text] [Related]
7. Aristolochic acid mutational signature defines the low-risk subtype in upper tract urothelial carcinoma.
Lu H; Liang Y; Guan B; Shi Y; Gong Y; Li J; Kong W; Liu J; Fang D; Liu L; He Q; Shakeel M; Li X; Zhou L; Ci W
Theranostics; 2020; 10(10):4323-4333. PubMed ID: 32292497
[No Abstract] [Full Text] [Related]
8. Renal cell carcinomas of chronic kidney disease patients harbor the mutational signature of carcinogenic aristolochic acid.
Jelaković B; Castells X; Tomić K; Ardin M; Karanović S; Zavadil J
Int J Cancer; 2015 Jun; 136(12):2967-72. PubMed ID: 25403517
[TBL] [Abstract][Full Text] [Related]
9. Balkan Endemic Nephropathy and the Causative Role of Aristolochic Acid.
Jelaković B; Dika Ž; Arlt VM; Stiborova M; Pavlović NM; Nikolić J; Colet JM; Vanherweghem JL; Nortier JL
Semin Nephrol; 2019 May; 39(3):284-296. PubMed ID: 31054628
[TBL] [Abstract][Full Text] [Related]
10. Analysis of TP53 mutation spectra reveals the fingerprint of the potent environmental carcinogen, aristolochic acid.
Hollstein M; Moriya M; Grollman AP; Olivier M
Mutat Res; 2013; 753(1):41-49. PubMed ID: 23422071
[TBL] [Abstract][Full Text] [Related]
11. Aristolochic Acid in the Etiology of Renal Cell Carcinoma.
Hoang ML; Chen CH; Chen PC; Roberts NJ; Dickman KG; Yun BH; Turesky RJ; Pu YS; Vogelstein B; Papadopoulos N; Grollman AP; Kinzler KW; Rosenquist TA
Cancer Epidemiol Biomarkers Prev; 2016 Dec; 25(12):1600-1608. PubMed ID: 27555084
[TBL] [Abstract][Full Text] [Related]
12. Genome-wide mutational signatures of aristolochic acid and its application as a screening tool.
Poon SL; Pang ST; McPherson JR; Yu W; Huang KK; Guan P; Weng WH; Siew EY; Liu Y; Heng HL; Chong SC; Gan A; Tay ST; Lim WK; Cutcutache I; Huang D; Ler LD; Nairismägi ML; Lee MH; Chang YH; Yu KJ; Chan-On W; Li BK; Yuan YF; Qian CN; Ng KF; Wu CF; Hsu CL; Bunte RM; Stratton MR; Futreal PA; Sung WK; Chuang CK; Ong CK; Rozen SG; Tan P; Teh BT
Sci Transl Med; 2013 Aug; 5(197):197ra101. PubMed ID: 23926199
[TBL] [Abstract][Full Text] [Related]
13. TP53 Mutational signature for aristolochic acid: an environmental carcinogen.
Moriya M; Slade N; Brdar B; Medverec Z; Tomic K; Jelaković B; Wu L; Truong S; Fernandes A; Grollman AP
Int J Cancer; 2011 Sep; 129(6):1532-6. PubMed ID: 21413016
[TBL] [Abstract][Full Text] [Related]
14. Urothelial carcinoma associated with the use of a Chinese herb (Aristolochia fangchi).
Nortier JL; Martinez MC; Schmeiser HH; Arlt VM; Bieler CA; Petein M; Depierreux MF; De Pauw L; Abramowicz D; Vereerstraeten P; Vanherweghem JL
N Engl J Med; 2000 Jun; 342(23):1686-92. PubMed ID: 10841870
[TBL] [Abstract][Full Text] [Related]
15. Balkan endemic nephropathy: an update on its aetiology.
Stiborová M; Arlt VM; Schmeiser HH
Arch Toxicol; 2016 Nov; 90(11):2595-2615. PubMed ID: 27538407
[TBL] [Abstract][Full Text] [Related]
16. Is aristolochic acid nephropathy a widespread problem in developing countries? A case study of Aristolochia indica L. in Bangladesh using an ethnobotanical-phytochemical approach.
Michl J; Jennings HM; Kite GC; Ingrouille MJ; Simmonds MS; Heinrich M
J Ethnopharmacol; 2013 Aug; 149(1):235-44. PubMed ID: 23806867
[TBL] [Abstract][Full Text] [Related]
17. Chinese herbs nephropathy and Balkan endemic nephropathy: toward a single entity, aristolochic acid nephropathy.
De Broe ME
Kidney Int; 2012 Mar; 81(6):513-5. PubMed ID: 22373701
[TBL] [Abstract][Full Text] [Related]
18. Aristolochic acid-associated urothelial cancer in Taiwan.
Chen CH; Dickman KG; Moriya M; Zavadil J; Sidorenko VS; Edwards KL; Gnatenko DV; Wu L; Turesky RJ; Wu XR; Pu YS; Grollman AP
Proc Natl Acad Sci U S A; 2012 May; 109(21):8241-6. PubMed ID: 22493262
[TBL] [Abstract][Full Text] [Related]
19. Cytotoxicity and genotoxicity of the carcinogen aristolochic acid I (AA-I) in human bladder RT4 cells.
Bellamri M; Brandt K; Brown CV; Wu MT; Turesky RJ
Arch Toxicol; 2021 Jun; 95(6):2189-2199. PubMed ID: 33938965
[TBL] [Abstract][Full Text] [Related]
20. TP53 mutation signature supports involvement of aristolochic acid in the aetiology of endemic nephropathy-associated tumours.
Nedelko T; Arlt VM; Phillips DH; Hollstein M
Int J Cancer; 2009 Feb; 124(4):987-90. PubMed ID: 19030178
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
